SeaLife Pharma – new generation of R&D

SeaLife Pharma® is an innovative marine biotechnology company focusing on the discovery and development of new bio-active compounds. Our research is based on the chemical diversity of unexplored marine microbes and broad experience in the anti-infective area at all relevant levels from basic research to clinical development. With Ecotargeting, a novel strategic approach, SeaLife has identified potential substances more specifically than based on traditional random collection.
In the last year, SeaLife discovered a range of highly active compounds which currently are in different stages of development and yielded several promising drug candidates.

History

SeaLife started as a project in late 2007 based on the Ecotargeting principle
In spring 2008, SeaLife acquired first grants from Accent NÖ (AplusB) and Aws (Pre-seed)
Assembling and installation of SeaLife’s R&D laboratory at the Campus Tulln/Austria in September 2008
Foundation of the SeaLife Pharma Ltd. in November 2008
Early 2009, participation in FFG/COIN project with FH Krems/Austria (anti-cancer screening of SeaLife’s substances)
March 2009, first co-operation agreement with the Heinrich-Heine University of Dusseldorf/Germany
Winner of the European Venture event in Budapest October 2009
Award “Most Innovative company of the month” in November 2009
Winner of the European Venture Summit in Düsseldorf, December 2009
Winner of Genius Award, December 2009
Winner of the Austrian ‘science2business Award 2010’, March 2010
March 2011: SeaLife Pharma secured its series ‘A’ funding of € 2.0 m from Tecnet Equity Ltd. and PPCapital AG